CEACAM5: Safety and Efficacy Outcome in Long-term Treatment with SAR408701 in Pts with NSQ NSCLC Prof Charles Ricordel - Synopsis below extracted from the video transcript.
Prof. Charles Ricordel discusses the safety and efficacy of SAR408701 in the long-term treatment of non-squamous non-small cell lung cancer (NSQ NSCLC) patients. SAR408701 is a monoclonal antibody that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), which is overexpressed in many cancer types, including NSQ NSCLC.
The study included 52 patients with advanced NSQ NSCLC who had received at least one prior line of chemotherapy. Patients received SAR408701 at a dose of 15 mg/kg every three weeks until disease progression or unacceptable toxicity. The primary endpoint of the study was safety, while secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
The results showed that SAR408701 was well-tolerated, with no dose-limiting toxicities or treatment-related deaths. The most common adverse events were fatigue, nausea, and decreased appetite. The ORR was 10%, while the DCR was 46%. The median PFS and OS were 1.9 months and 8.2 months, respectively.
Prof. Ricordel notes that while the overall efficacy results were modest, there were some promising responses in specific subgroups of patients, including those with low CEACAM5 expression and those who received SAR408701 as a maintenance treatment after initial chemotherapy. He also emphasizes the need for further research to identify biomarkers that could predict response to SAR408701 and improve patient selection.
In conclusion, SAR408701 was found to be safe and tolerable in the long-term treatment of NSQ NSCLC patients, with modest efficacy results. Further research is needed to identify potential biomarkers and improve patient selection for this treatment.
